VIII. Treatment of chronic lymphocytic leukaemia, where are we heading?

Hematological Oncology

Volumn 33, Issue S1, 2015, Pages 46-49

  O'Brien, Susan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CLL; Therapy B cell receptor inhibitor

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD20 ANTIBODY; CHLORAMBUCIL; IBRUTINIB; IDELALISIB; OBINUTUZUMAB; OFATUMUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR PROTEIN;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; ENZYME INHIBITION; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); FEMALE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; METABOLISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, B-CELL;

EID: 84930701624     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2216     Document Type: Article

References (10)

1. Geode V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101-1110.
2. Hillmen P, Robak T, Janssens A, et al. ASH 2013 Abstract 528.
3. ASH Abstracts. 2014.
4. Byrd J, Furman R, Coutre S, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32-42.
5. O'Brien S, Furman RR, Coutre SE, et al. American Society of Clinical Oncology 2014, PCYC 1102/1103.
6. Byrd J, Brown J, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213-223.
7. Woyach J, Furman R, Liu T, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014; 370: 2286-2294.
8. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014; 123(22): 3390-3397.
9. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370(11): 997-1007.
10. Barrientos JC, O'Brien S, Brown JR, et al. ASH 2014.